Who We Are
What We Do
Corporate Responsibility
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals Announces the Approval for the Insulin Pen in Thailand
Gan & Lee Pharmaceuticals Announces the Approval for the Insulin Pen in Thailand

BEIJING, CHINA, April 15, 2022 — Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that our Insulin Delivery Device – the Insulin Pen has been approved by the Thailand Food and Drug Administration(TFDA) through the cooperation between our Thai partner and Gan & Lee.



Gan & Lee Pharmaceuticals’ Insulin Delivery Device – Insulin Pen

The approved Insulin Pen can be used with the Gan & Lee 3mL cartridge insulin penfill. By adjusting the dose knob, patients are allowed to set 1-60 units (U) of insulin for administration. The minimum scale of the pen is accurate to 1 unit (U), which can meet the needs of diabetic patients for daily injection.


Thailand is one of the 39 members of the IDF Western Pacific Region(WPR)1. In accordance with the IDF Atlas 10th edition, as of 2021, about 6.1 million adults (aged 20 to 79) have diabetes in Thailand, ranking the country fourth in the Western Pacific region2. The approval not only means that Gan& Lee's own insulin pen officially enters into the Thai medical device market, but also paves the way as a supporting product for our insulin glargine injection which the company anticipates will be approved in Thailand .


"I am very pleased to see our insulin pen has been approved in Thailand, which is great progress in the overseas market. Being patient-centered, we are always dedicated to enabling more people with diabetes around the world to have access to Gan & Lee’s products.” said Jason Wu, Director of the International Business Affairs Department in Gan & Lee Pharmaceuticals.



1. IDF Western Pacific members. https://www.idf.org

2. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin®25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely the reusable insulin injection pen (GanleePen™), and the disposable pen needle (GanleeFine®).


In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 

Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号
Our websites


I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.